Accredited Education

Closing Gaps in Invasive Candidiasis Care

Invasive candidiasis, the most common invasive fungal infection, remains a significant source of morbidity and mortality. Despite advances in therapeutics for invasive candidiasis, gaps persist in optimal initial therapy selection, source control, and transitions of care, particularly when patients have chronic or disseminated candidiasis. In this activity, based on a live Town Hall held on September 29, 2025, mycology experts use real-world case studies and a patient perspective to highlight practical strategies for improving clinical decision-making and patient-centered outcomes for invasive candidiasis.

Advanced Molecular Techniques in Infectious Diseases: Case Studies in Mycology

Join us for this 1-hour accredited activity, based on a town hall recorded on July 21, 2025, in which mycology experts Drs Luis Ostrosky-Zeichner and Angel Desai discuss the appropriate use of advanced diagnostic techniques as part of an overall fungal diagnostic schema in pediatric hematology/oncology, intensive care, and immunocompromised host settings.. Learn how to leverage all of the available fungal diagnostic tools to reduce diagnostic delays and improve outcomes for patients with invasive fungal infections.

The activities below are no longer available for credit, but are available for review.

Case Studies in Optimal Management of Invasive Candidiasis

This multimedia CME/CPE enduring activity from the live MSGERC Town Hall held on July 7, 2023, discusses the newest trends in the management of invasive candidiasis. The expert faculty discuss hospital and health care-associated infection scenarios: a patient coming in from a long-term acute care hospital (LTACH), an invasive fungal infection in a stem cell transplant patient, and an intra-abdominal infection in a hospitalized surgical patient.

New CME/CPE/CNE Activity! Treatment Failure in Mycology: Addressing the Root Cause

This case-based CME/CPE/CNE activity is focused on addressing causes of treatment failure in serious fungal infections to improve patient outcomes. Using a multidisciplinary approach, the faculty will address inadequate testing, antifungal resistance, adherence issues, source control, and pharmacologic issues, including inadequate use of therapeutic drug monitoring. The cases will span resistant dermatophytes, coccidioidomycosis, candidemia, and an invasive mold infection.

New CME/CNE/CPE Activity! Community-Acquired Pneumonia: When to Think Fungus

This CME/CNE/CPE activity will explore community-acquired pneumonia cases, illustrating when to consider coccidioidomycosis, blastomycosis, and histoplasmosis endemic mycoses. The activity will feature use of CDC/MSGERC/CSG algorithms to recognize patients at risk for these infections as well as diagnostic strategies. This activity was developed for a target audience of primary care providers, specialists who prescribe biologics, pulmonologists, as well as urgent care and emergency medicine providers who see patients with community acquired pneumonia.

New! Challenging Invasive Fungal Infections: Current and Emerging Pharmacologic Strategies

The optimal management of invasive fungal infections requires a collaborative approach focused on optimal agent selection, pharmacologic optimization, and a clear strategy to identify and address treatment failure. For some pathogens, the challenge is further exacerbated by the limitations of existing regimens. Fortunately, emerging therapeutic approaches show promise for a range of invasive mycoses. In this activity, featuring cases from the virtual live event MSGERC Town Hall: Challenging Invasive Fungal Infections,  mycology experts illustrate strategies to optimize the management of challenging invasive mold and Coccidioides infections. The activity features mycology experts Drs Luis Ostrosky-Zeichner, George R. Thompson III, and James Lewis, with additional commentary from Dr Nathan Wiederhold.

New! Managing Invasive Candidiasis: Key Strategies to Make a Difference

In this activity, Drs Ostrosky-Zeichner and Peter Pappas illustrate strategies to make a difference in the management of invasive candidiasis. Using an infographic approach to reinforce key concepts, they make a compelling call to action for more state-of-the-art management of this common fungal infection.

New! Challenging Invasive Fungal Infections: Risk Assessment and Diagnosis

Thinking fungus, diagnosing the fungal pathogen to the genus and species level, and addressing antifungal resistance are key steps to improving outcomes for invasive fungal infections (IFIs). This activity, featuring cases from the virtual live event MSGERC Town Hall: Challenging Invasive Fungal Infections, is designed to help clinicians identify at-risk patients and secure the IFI diagnosis. It will highlight the problem with low awareness of endemic mycoses as potential causes of CAP as well as the importance of appropriate use of antifungal susceptibility testing. The activity features mycology experts Drs Luis Ostrosky-Zeichner, George R. Thompson III, and Nathan Wiederhold, with additional commentary by Dr James Lewis.

COVID-19—Associated Invasive Fungal Infections: Multidisciplinary Management

Accredited for physicians, pharmacists, and nurses (including pharmacotherapy credit for APRNs)

In this multimedia, case-based CE activity, a multidisciplinary panel, including a medical mycologist, infectious diseases pharmacist, pulmonologist, and intensivist, weigh in on challenging COVID-19-associated IFI cases. The activity addresses:

• Candidemia
• COVID-19-associated pulmonary aspergillosis
• Cryptococcosis

COVID-19–Associated Invasive Fungal Infections: Expert Guidance on Cases From the Community Earn up to 1.5 AMA PRA Category 1 Credits(TM).

In this interactive, case-based CME activity, mycology experts Drs George R. Thompson, III; Dimitrios Kontoyiannis; and Minh-Hong Thi Nguyen apply the Care Step Pathway and other tools from this initiative in the management of challenging COVID-19–associated IFI cases submitted by community clinicians. The activity addresses:

• COVID-19—associated pulmonary aspergillosis (CAPA)
• COVID-19–associated mucormycosis
• Coccidioidomycosis reactivation after recovery from COVID-19
• Pharmacologic considerations relevant to COVID-19 patients